These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27484655)

  • 1. Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems.
    Liu F; Shimakami T; Murai K; Shirasaki T; Funaki M; Honda M; Murakami S; Yi M; Tang H; Kaneko S
    Sci Rep; 2016 Aug; 6():30939. PubMed ID: 27484655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection.
    Koizumi Y; Ohashi H; Nakajima S; Tanaka Y; Wakita T; Perelson AS; Iwami S; Watashi K
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1922-1927. PubMed ID: 28174263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of preclinical antimalarial drugs, which can overcome direct-acting antivirals-resistant hepatitis C viruses, using the viral reporter assay systems.
    Ueda Y; Dansako H; Satoh S; Kim HS; Wataya Y; Doi H; Ikeda M; Kato N
    Virus Res; 2017 May; 235():37-48. PubMed ID: 28322919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A proof-of-concept study in HCV-infected Huh7.5 cells for shortening the duration of DAA-based triple treatment regimens.
    Li H; Tan JL; Li JR; Liu NN; Chen JH; Lv XQ; Zou LL; Dong B; Peng ZG; Jiang JD
    Biomed Pharmacother; 2019 Aug; 116():108976. PubMed ID: 31103827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
    Tao W; Gan T; Lu J; Zhong J
    Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
    Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
    Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus.
    Lee WP; Lan KL; Liao SX; Huang YH; Hou MC; Lan KH
    Am J Chin Med; 2018; 46(4):835-852. PubMed ID: 29737209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 96-well based analysis of replicon elimination with the HCV NS5A replication complex inhibitor daclatasvir.
    O'Boyle DR; Nower PT; Sun JH; Fridell R; Wang C; Valera L; Gao M
    J Virol Methods; 2013 Oct; 193(1):68-76. PubMed ID: 23684844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus resistance to the new direct-acting antivirals.
    Esposito I; Trinks J; Soriano V
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced fitness of hepatitis C virus increases resistance to direct-acting antivirals.
    Soni S; Singh D; Aggarwal R; Veerapu NS
    J Gen Virol; 2022 Feb; 103(2):. PubMed ID: 35133954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.
    Ottosen S; Parsley TB; Yang L; Zeh K; van Doorn LJ; van der Veer E; Raney AK; Hodges MR; Patick AK
    Antimicrob Agents Chemother; 2015 Jan; 59(1):599-608. PubMed ID: 25385103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
    Bagaglio S; Uberti-Foppa C; Morsica G
    Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.
    Comarmond C; Garrido M; Pol S; Desbois AC; Costopoulos M; Le Garff-Tavernier M; Si Ahmed SN; Alric L; Fontaine H; Bellier B; Maciejewski A; Rosenzwajg M; Klatzmann D; Musset L; Poynard T; Cacoub P; Saadoun D
    Gastroenterology; 2017 Jun; 152(8):2052-2062.e2. PubMed ID: 28274850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.